NCT06993844 2026-03-17
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Ensem Therapeutics
Phase 1/2 Recruiting
Ensem Therapeutics
Eli Lilly and Company
Memorial Sloan Kettering Cancer Center
Stemline Therapeutics, Inc.
University Hospital, Strasbourg, France
Maastricht University Medical Center